摘要
Pancreatic adenocarcinoma is the fifth leading cause of cancerrelateddeathsworldwide,andthisincidenceisprojectedtoincreasefurtherinfuturedecades[1].Furthermore,despiteyears ofattemptingtoimprovetreatmentforpatientswithpancreatic adenocarcinoma, the 5-year overall survival rate remains low at <7%[2]. Thus, this cancer is devastating, and effective treatment
基金
supported by grants from the National Science Foundation for Distinguished Young Scholars of China(81625016)
the National Natural Science Foundation of China(81472670,81402397,and 81402398)
the Outstanding Academic Leader Program of the "Technological Innovation Action Plan" in Shanghai Science and Technology Commission(18XD1401200)
the Young Talented Specialist Training Program of Shanghai
作者简介
Corresponding author:Xian-Jun Yu,Department of Pancreatic Surgery,Fudan University Shanghai Cancer Center,Shanghai Pancreatic Cancer Institute,Pancreatic Cancer Institute,Fudan University,Shanghai 200032,China E-mail addresses:yuxianjun@fudanpci.org,yuxianjun@fudan.edu.cn(X.-J.Yu).
